These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 3030711)

  • 1. Biological activities of sarcosine1-angiotensin I in man.
    Kono T; Taniguchi A; Imura H; Oseko F; Khosla MC
    Endocrinol Jpn; 1986 Oct; 33(5):583-8. PubMed ID: 3030711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No substrate specificity of converting enzyme for N-terminal substituted angiotensin I in man.
    Kono T; Taniguchi A; Oseko F; Imura H; Khosla MC
    Clin Exp Hypertens A; 1987; 9(2-3):261-5. PubMed ID: 3038386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Agonistic activities of isoleucine8-angiotensin II in man.
    Kono T; Taniguchi A; Imura H; Oseko F; Khosla MC
    Endocrinol Jpn; 1985 Oct; 32(5):701-8. PubMed ID: 3912161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relative biological activities of Asn1-,Val5-angiotensin II, Ile5-angiotensin II and Sar1-angiotensin II in man.
    Kono T; Taniguchi A; Imura H; Oseko F; Khosla MC
    Life Sci; 1985 Jul; 37(4):365-9. PubMed ID: 3892218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives.
    Azizi M; Chatellier G; Guyene TT; Murieta-Geoffroy D; Ménard J
    Circulation; 1995 Aug; 92(4):825-34. PubMed ID: 7641363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vasoconstrictor effect of the angiotensin-converting enzyme-resistant, chymase-specific substrate [Pro(11)(D)-Ala(12)] angiotensin I in human dorsal hand veins: in vivo demonstration of non-ace production of angiotensin II in humans.
    McDonald JE; Padmanabhan N; Petrie MC; Hillier C; Connell JM; McMurray JJ
    Circulation; 2001 Oct; 104(15):1805-8. PubMed ID: 11591618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin-converting enzyme gene polymorphism has no influence on the circulating renin-angiotensin-aldosterone system or blood pressure in normotensive subjects.
    Lachurié ML; Azizi M; Guyene TT; Alhenc-Gelas F; Ménard J
    Circulation; 1995 Jun; 91(12):2933-42. PubMed ID: 7796503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological activities of angiotensin II-(1-6)-hexapeptide and angiotensin II-(1-7)-heptapeptide in man.
    Kono T; Taniguchi A; Imura H; Oseko F; Khosla MC
    Life Sci; 1986 Apr; 38(16):1515-9. PubMed ID: 3702589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pressor activity of angiotensin II-(2-7)-hexapeptide in man.
    Kono T; Taniguchi A; Imura H; Oseko F; Khosla MC
    Endocrinol Jpn; 1985 Oct; 32(5):767-9. PubMed ID: 3912163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetic studies of the pharmacologic response to captopril in rats. I. Role of the renin-angiotensin system.
    Endoh M; Suzuki M; Katayama K; Kakemi M; Koizumi T
    J Pharmacobiodyn; 1989 Jan; 12(1):1-9. PubMed ID: 2542516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular angiotensin-converting enzyme expression regulates local angiotensin II.
    Müller DN; Bohlender J; Hilgers KF; Dragun D; Costerousse O; Ménard J; Luft FC
    Hypertension; 1997 Jan; 29(1 Pt 1):98-104. PubMed ID: 9039087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Captopril enhances vascular and adrenal responsiveness to angiotensin II in essential hypertension.
    Koletsky RJ; Gordon MB; LeBoff MS; Moore TJ; Dluhy RG; Hollenberg NK; Williams GH
    Clin Sci (Lond); 1984 Mar; 66(3):299-305. PubMed ID: 6362960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin III and pressor responsiveness in 3-day renal artery stenosis rabbits.
    Johnson JA; Dostal DE; Elsberry-Gonder A
    Am J Physiol; 1990 Feb; 258(2 Pt 2):H540-8. PubMed ID: 2178447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of intrarenal ACE-inhibition estimated from the renal response to angiotensin I and II in humans.
    Vos PF; Boer P; Braam B; Koomans HA
    Kidney Int; 1995 Jan; 47(1):274-81. PubMed ID: 7731158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Captopril improves postresuscitation hemodynamics protective against pulmonary embolism by activating the ACE2/Ang-(1-7)/Mas axis.
    Xiao HL; Li CS; Zhao LX; Yang J; Tong N; An L; Liu QT
    Naunyn Schmiedebergs Arch Pharmacol; 2016 Nov; 389(11):1159-1169. PubMed ID: 27449068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Responses to converting enzyme and renin inhibition. Role of angiotensin II in humans.
    Fisher ND; Allan D; Kifor I; Gaboury CL; Williams GH; Moore TJ; Hollenberg NK
    Hypertension; 1994 Jan; 23(1):44-51. PubMed ID: 8282330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Compartmentalization of angiotensin II generation in the dog heart. Evidence for independent mechanisms in intravascular and interstitial spaces.
    Dell'Italia LJ; Meng QC; Balcells E; Wei CC; Palmer R; Hageman GR; Durand J; Hankes GH; Oparil S
    J Clin Invest; 1997 Jul; 100(2):253-8. PubMed ID: 9218500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of ACE inhibition on pressor, renal vascular, and adrenal responses to infusion of angiotensin I in normal subjects eating a low-salt diet.
    Hollenberg NK; Fisher ND; Price DA; Williams GH
    Am J Hypertens; 2000 May; 13(5 Pt 1):498-503. PubMed ID: 10826400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of angiotensin I-converting enzyme inhibitor, SQ 14225, in nomal men.
    Kono T; Ikeda F; Oseko F; Imura H; Endo J
    Endocrinol Jpn; 1979 Jun; 26(3):411-8. PubMed ID: 383475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Should the use of short acting angiotensin-converting enzyme inhibitors be abandoned?
    Erman A; Boner G; van Dijk DJ
    J Renin Angiotensin Aldosterone Syst; 2000 Dec; 1(4):365-8. PubMed ID: 11967825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.